MYND Life Sciences Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Wilfred A. Jefferies
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 733 Finns Road Kelowna BC Canada V1X 5B7
- IPO Date
- Sep 22, 2021
- Website
- myndsciences.com
- Similar Companies
- Business
- MYND Life Sciences Inc is a clinical-stage life sciences company focused on developing and commercializing neuro-pharmaceutical drugs and diagnostic tools targeting mental health disorders, primarily Major Depressive Disorder (MDD) and Treatment-resistant Depression (TRD). The company develops proprietary biomarker tests designed to diagnose and monitor depression, alongside novel psychedelic pharmaceuticals focusing on non-hallucinogenic psilocybin analogs with enhanced bioactivity for safer and more effective treatments. MYND's product pipeline includes drug candidates such as MYND-604 and MYND-778, which target neuro-inflammatory pathways linked to depression and other related diseases including autoimmune disorders, multiple sclerosis, and Alzheimer's disease. Founded in Vancouver, British Columbia, MYND operates primarily in Canada but advances its clinical and research collaborations internationally, including funding-supported studies at Monash University in Australia. In the last two years, MYND has strategically reduced debt by converting $3.5 million of debentures to equity shares, improving its financial stability. The company has successfully navigated regulatory and operational challenges to position its depression biomarker test for imminent commercial availability, targeting initial market entry as a pioneering diagnostic tool in mental health. Additionally, MYND expanded its executive leadership by appointing new board members and management to support its commercialization and development efforts. MYND Life Sciences specializes in neuro-pharmaceutical research and development of new biological and chemical entities derived from psychedelic compounds aimed at treating neuro-inflammatory and mental health conditions. It focuses on advancing rigorous science with intellectual property protections to deliver unique molecular concepts that address unmet needs in treating depression and inflammation-related diseases. The company continually develops its clinical-stage products towards FDA approval and commercialization, emphasizing personalized patient management through its biomarker technology and therapeutic agents. Recent strategic moves reflect a commitment to strengthening governance, reducing liabilities, and ensuring robust progression of its novel drug pipeline and diagnostic platform.
MYND Life Sciences Announces Shares for Debt Transaction
MYND Life Sciences Announces the Issuance of 4,000,001 Shares at $0.71/share
MYND Life Sciences Announces Successful Conclusion of Debenture Settlement Agreement and Leadership Transition
MYND Life Sciences Announces Strategic Debt Reduction and New Board Member Appointment
MYND Life Sciences Announces Proposed Share Issuance to Remove Debenture and $3.440 M in debt on business
MYND Life Sciences Announces New Director & Update on the Proposed Merger with Cava Healthcare Inc.
MYND Life Sciences Inc. Announces the Appointment of Mr. John Campbell as President and Chief Executive Officer
Dr. Lyle Oberg Appointment as Board Chair of Alberta Health Services and Executive Chair of MYND Life Sciences
MYND Life Sciences Inc. Announces Non-Binding LOI to enable merger with Cava Healthcare Inc.
MYND Life Sciences Announces Update on Payment Obligations Under Unsecured Convertible Debentures